Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | MEDI1873 |
Synonyms | |
Therapy Description |
MEDI1873 (Efgivanermin) is a glucocorticoid-induced tumor necrosis factor related-protein (GITR) agonist that is comprised of an IgG1 Fc domain, coronin 1A trimerization domain, and a GITRL extracellular domain, which when administered may lead to T-cell activation, thereby promoting antitumor immunity (PMID: 28405505). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MEDI1873 | MEDI-1873|MEDI 1873|Efgivanermin | MEDI1873 (Efgivanermin) is a glucocorticoid-induced tumor necrosis factor related-protein (GITR) agonist that is comprised of an IgG1 Fc domain, coronin 1A trimerization domain, and a GITRL extracellular domain, which when administered may lead to T-cell activation, thereby promoting antitumor immunity (PMID: 28405505). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|